Navigation Links
New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder

ssors experienced by women may contribute to a major depressive episode.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialization (including with respect to our pipeline products), drug pricing and payment for our products by government and third-party-payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Walmart (NYSE: WMT ) and Eli Lilly and Company ... affordable insulin option for people with diabetes.   , ... Beginning in mid-September, Lilly,s Humulin ® brand of ... name Humulin ® ReliOn ®, including 10 mL vials of Humulin® ...
... NASHVILLE, Tenn. , June 21 Emdeon Inc. (NYSE: ... payment cycle management solutions, today announced the acquisition of Chapin Revenue ... is a leading technology-enabled provider of hospital-based revenue cycle services including ... , , ...
Cached Medicine Technology:Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 2Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 4Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 5Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 2Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 3Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 4
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... growth worsens ovarian cancer, but its production can be stifled ... nanoparticle, a research team led by scientists at The University ... Journal of the National Cancer Institute. , "The protein interleukin-8 ... senior author Anil Sood, M.D., professor in the M. D. ...
... Works to Help Hollywood ,Stay Sane in an Insane ... ... Roy, M.A., "The,Industry Therapist" ( http://www.theIndustryTherapist.com ) is asking the,question why the ... Spears, mental illness., "Heath Ledger,s death is being treated with kid ...
... Feb. 26 Hologic, Inc.,(Nasdaq: HOLX ) today ... at the Raymond James & Associates 29th Annual,Institutional Investors ... Grand Cypress Hotel in Orlando, FL., Interested parties ... of,Hologic,s investor presentation on Monday, March 3, 2008 at ...
... clots, study says, , , TUESDAY, Feb. 26 (HealthDay News) ... associated with cancer treatment-related anemia may do more harm ... , The drugs -- erythropoiesis-stimulating agents (ESAs) -- increase ... risk of blood clots known as venous thromboembolisms (VTE) ...
... Increased ... 3.85% and 2.96%, Respectively, MEXICO CITY, Feb. 26 ... one of the leading Mexican,distributors of pharmaceutical products, beauty aids, ... its consolidated financial and operating results for the fourth,quarter of ...
... 26 Schnitzer West announced today,that one of the ... Coast gym in The Shops at The Bravern in ... time to meet the needs of approximately 2,300,Microsoft employees ... of the,project beginning this fall., DavidBartonGym will offer ...
Cached Medicine News:Health News:Researchers identify and shut down protein that fuels ovarian cancer 2Health News:Researchers identify and shut down protein that fuels ovarian cancer 3Health News:Hologic to Present at the Raymond James & Associates 29th Annual Institutional Investors Conference 2Health News:Anemia Drugs for Cancer Patients Increase Death Risk 2Health News:Anemia Drugs for Cancer Patients Increase Death Risk 3Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 2Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 3Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 4Health News:World-Famous DavidBartonGym Buffs up the Bravern 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 3
... This unique system uses prolene as thread-guide ... The hollow Ritleng Probe is inserted into the ... fed through it. The probe is then withdrawn ... mm 0.64 mm diam silicone tubing into place. ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... collarette conforms to natural anatomy of ... Pre-loaded on disposable inserter/dilator instrument for ... forceps. The Micro-Large plugs feature the ... natural shape of the eyelid. The ...
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Medicine Products: